JCR Pharmaceuticals’ Research Presentations at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders

JCR Pharmaceuticals’ Research Presentations at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders

JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, announced today that it presented new clinical data in a poster session at the 18th International Symposium on MPS and Related Lysosomal Diseases, which was held June 4-7, 2026, in Florence, Italy.

“Due to the protective blood-brain barrier, lysosomal storage disorders historically have been challenging to treat due to the inability to deliver a therapy into the central nervous system. With our J-Brain Cargo® platform technology, we have the potential to address the progressive neurological symptoms associated with these rare and life-limiting diseases, many of which have inadequate treatment options or no approved therapies available,” said Hiroyuki Sonoda, Ph.D., President and Chief Scientific Officer of JCR Pharmaceuticals. “The data presented at this symposium demonstrate the safety and efficacy evidence of JR-171 (lepunafusp alfa) in people with mucopolysaccharidosis type I (MPS I) and highlight its potential. We look forward to sharing additional data from our J-Brain Cargo® platform technology as they are available. We wish to thank all of the patients who have participated in our clinical programs and their families, clinical investigators, and other partners who continue to support our work.”